NSCLC, early stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
Authors:
- P.M. FordePFP.M. Forde
- K.N. SmithKSK.N. Smith
- J.E. ChaftJCJ.E. Chaft
- M. HellmannMHM. Hellmann
- T. MerghoubTMT. Merghoub
- J.D. WolchokJWJ.D. Wolchok
- S.C. YangSYS.C. Yang
- R.J. BattafaranoRBR.J. Battafarano
- E. GabrielsonEGE. Gabrielson
- C.S. GeorgiadesCGC.S. Georgiades
- F. VerdeFVF. Verde
- G.L. RosnerGRG.L. Rosner
- 13 October 2016
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi576
Abstract
Background: Nivolumab is a PD-1 inhibitor that has demonstrated durable responses and improved survival in patients (pts) with previously treated, metastatic non-small-cell lung cancer (NSCLC). This is the first report of neoadjuvant PD-1 blockade in pts with early stage NSCLC.Keywords
Funding Information
- Bristol-Myers Squibb